Global Lewy Body Dementia Treatment Market Segments 2024, Forecast To 2033
5 Mar, 2024
The Lewy body dementia treatment market has shown strong growth, increasing from $4.14 billion in 2023 to $4.41 billion in 2024, with a 6.5% CAGR. Growth in the historic period is attributed to supportive care, family education, regulatory approvals, multidisciplinary care, psychosocial interventions. Expecting strong growth, the market is projected to reach $5.68 billion in 2028 with a 6.6% CAGR, driven by neurology advancements, research initiatives, precision medicine, collaborative healthcare, and telemedicine expansion. Major trends include family support, integrated care, personalized treatments, non-pharmacological interventions, and digital health solutions.
Global Lewy Body Dementia Treatment Market Key Driver
The rising prevalence of brain-related disorders propels the growth of the Lewy body dementia treatment market. These disorders impair brain function, with a projected increase to 9.3 million cases in the US by 2060, as reported by the American Heart Association Inc. Globally, one in every six people suffers from a brain disease, with an expected 1 billion people affected worldwide by 2021. Lewy body dementia treatments target symptoms like hallucinations, confusion, and drowsiness, enhancing brain chemicals to improve alertness and cognition.
Get A Free Sample Of The Global Lewy Body Dementia Treatment Market ReportGlobal Lewy Body Dementia Treatment Market Segments
The lewy body dementia treatment market covered in this report is segmented –
1) By Drug Type: Antidepressants, Antipsychotic Drugs, Benzodiazepine, Carbidopa-Levodopa, Cholinesterase inhibitors, Modafinil
2) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
3) By Application: Alzheimer’s disease, Dementia, Parkinson’s disease
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the Lewy body dementia treatment market in 2023. The regions covered in the lewy body dementia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Lewy Body Dementia Treatment Industry Players
Mallinckrodt Pharmaceuticals Co.; BioArctic AB; Sumitomo Pharma Co. Ltd.; Jazz Pharmaceuticals Inc.; Allergan plc; Novartis International AG; Pfizer Inc.; Bayer AG; Amneal Pharmaceuticals LLC.; Boehringer Ingelheim International GmbH.; Merck & Co. Inc.; Abbott Ltd.; B Braun SE; Biogen Inc.; Biohaven Pharmaceutical Holding Company Ltd.; BioMarin Pharmaceutical Inc.; Blairex Laboratories Inc.; Blink Health LLC; Blueprint Medicines Corporation; Bristol Myers Squibb Company; Calliditas Therapeutics AB; Catalyst Pharmaceuticals Inc.; Chiesi USA Inc.; Clovis Oncology Inc.; Coherus Biosciences Inc.; CooperSurgical Inc.; Covis Pharmaceuticals Inc.; Genzyme Corporation; GlaxoSmithKline plc; Eisai Co. Ltd.; Bausch Health Companies Inc.; Hisamitsu Pharmaceutical Co. Inc.; Lundbeck Inc.
Get The Full Global Lewy Body Dementia Treatment Market Report
AIOps Lewy Body Dementia Treatment Market Overview
Lewy body dementia treatment refers to medications and nonmedical therapies, such as physical, occupational, and speech therapies, to manage symptoms as much as possible. The treatment is used for the healing and control of some of the symptoms and to reduce hallucinations, confusion, drowsiness, movement problems, and disturbed sleep.
Lewy Body Dementia Treatment Global Market Report 2023 provides data on the global lewy body dementia treatment market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The lewy body dementia treatment market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.